A trial fibrillation (AF) is a major risk factor for thromboembolic stroke. 1 Oral anticoagulants (OACs) reduce stroke risk in AF by 60% to 70%, 2, 3 but their uptake is suboptimal. 4, 5 Risk factors for stroke are generally well recorded in UK primary care electronic health records, providing an opportunity for automated risk assessment. We developed a software tool AURAS-AF (Automated Risk Assessment for Stroke in Atrial Fibrillation) within a web-based electronic health record system and conducted a cluster-randomized trial to measure its impact and confirm its safety. 6 
Methods
This was a cluster-randomized trial across practices in South East and Central England.
Intervention
The AURAS-AF tool drew on the data in the records of patients with AF and identified those fulfilling the eligibility criteria for OAC at that time. 7 It functioned in 2 ways: 1. At the start of the trial, practices were asked to invite a list of eligible patients for a discussion over anticoagulants. 2. If a patient identified as eligible for but not using OAC was seen at the practice by a clinician, a screen reminder message would appear. The tool was designed to challenge clinicians to justify treatment decisions at the point of care when the patient would be present. There was no requirement imposed by the trial to adhere to guidelines or follow any specific treatment pathway.
Background and

Control Practices
Practices allocated to the control arm continued to provide usual care to AF patients, including the requirements of the Quality and Outcomes Framework funding system. 8 
Outcome Measures
Primary Outcome
The primary outcome was the proportion of patients eligible for OAC who were currently prescribed an OAC at the end of the 6-month intervention period.
Secondary Outcomes
(1) Proportion with CHADS 2 score ≥2 currently prescribed OAC at 6 months; (2) Practices were asked to report instances of inappropriate clinical or prescribing decisions related to anticoagulation in patients with AF; Incidences of (3) thromboembolic stroke, transient ischemic attack, or systemic (arterial) thromboembolism; (4) hemorrhagic stroke and other hemorrhagic events; Incidence rates for the following events were added on the advice of the Data Monitoring Committee: (5) thromboembolic stroke; (6) transient ischemic attack; (7) systemic thromboembolism; (8) hemorrhagic stroke; (9) other hemorrhagic events; (10) unspecified stroke events; (11) all-cause stroke (thromboembolic, hemorrhagic, or unspecified).
All outcomes were measured at 6 months and repeated at 12 months (6 months after the end of the intervention period).
Audit of Cardiovascular Events
Each thromboembolic or hemorrhagic event occurring during the intervention period was investigated to identify whether it might have resulted from use of the software, for instance, through inappropriate prescribing decisions.
Allocation
Practices were randomized with an allocation ratio of 1:1 and minimized on practice list size, and proportion of eligible patients with AF prescribed OACs at baseline. 
Data Collection
Anonymized outcome data from the practices were extracted via a virtual private network linked to Oxford University. This source includes all electronically coded information, including diagnoses and medication.
Sample Size
We estimated that a sample of 46 practices would be needed for 95% power to detect a relative difference of 25% in the primary outcome with 5% significance. 6 
Statistical Analysis
Statistical analyses were undertaken using SPSS version 22 and Stata 13 on an intention to treat basis. Cluster summary measures were analyzed using a weighted linear regression model, with the minimization variables fitted as covariates. If assumptions of linear regression were violated, a Mann-Whitney U test was applied.
Results
We approached 570 potentially eligible practices; 70 expressed interest, and 47 were randomized (Figure) . One withdrew during the first 3 months of the trial, leaving 46 in the intention-to-treat sample. These provided a combined patient population of 359 937 with 6429 patients with AF at baseline (February 20, 2014), of which 5339 (83%) were eligible for OAC, and of these, 3340 (62.6%) were already treated. The population characteristics were similar in each arm (Table 1) .
Primary Outcome
The mean proportion (SD) of eligible patients prescribed OAC at 6 months was 66.3% (9.25) in the intervention arm and 63.9% (9.46) in the control arm. The adjusted mean difference (95% confidence interval) was 1.21% (−0.72 to 3.13); P=0.213.
Secondary Outcomes
The proportion in the subgroup with a CHADS 2 score ≥2 prescribed anticoagulants at the end of the study was not significantly different between trial arms. There were no reports of inappropriate clinical or prescribing decisions or cardiovascular events triggered by use of the software. Practice-based searches supporting the cardiovascular event audit confirmed the validity of the remote data extraction. Table 2 gives the incidence of cardiovascular events during the 6-and 12-month time periods after randomization. The increased rate of thromboembolic events in the intervention arm is because of a higher rate of transient ischemic attack diagnosis, with no increase in thromboembolic stroke or unspecified stroke. In fact, there is a reduction of borderline significance in strokes of all types (P=0.06) and of hemorrhage (P=0.054) at 12 months.
Discussion
Strengths and Limitations
This was a pragmatic randomized trial involving a diverse range of practices across a wide geographical area using a modern, web-based electronic health record platform. Figure) . The other searches were unaffected.
‡Mean (SD). §P value obtained from weighted linear regression.
